Lyndra Therapeutics, Inc.
Lyndra Therapeutics is dedicated to reinventing medicine through innovative long-acting oral therapies. Their proprietary LYNX™ drug delivery platform aims to deliver medicine for a week or longer in an oral form, significantly improving medication adherence and patient experience. The company was founded in 2015, emerging from technology developed at MIT, and has achieved rapid progress with multiple therapies in development across various therapeutic areas. Lyndra's culture emphasizes diversity, inclusion, innovation, and a mission to create game-changing treatments for a healthier world.
Industries
Nr. of Employees
medium (51-250)
Lyndra Therapeutics, Inc.
65 Grove Street, Suite 301, Watertown, MA 02472
Patents
Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
US-11576859-B2
View Details
Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
US-11576859-B2
View DetailsProducts
Long-acting oral drug delivery platform
A capsule-based oral delivery platform designed to release medication over days to weeks from a single dose, compatible with multiple small-molecule APIs and intended to improve adherence and enable weekly or monthly oral dosing.
Long-acting oral drug delivery platform
A capsule-based oral delivery platform designed to release medication over days to weeks from a single dose, compatible with multiple small-molecule APIs and intended to improve adherence and enable weekly or monthly oral dosing.
Services
Collaborative development and partnership opportunities to apply the long-acting oral delivery platform to partner APIs and programs, including public-health collaborations.
In-house GMP manufacturing capability for clinical and commercial production of long-acting oral dosage forms, and collaborations for commercial manufacturing scale-up.
Design and conduct of clinical trials including early-stage PK/safety studies and pivotal efficacy trials for oral long-acting formulations.
Collaborative development and partnership opportunities to apply the long-acting oral delivery platform to partner APIs and programs, including public-health collaborations.
In-house GMP manufacturing capability for clinical and commercial production of long-acting oral dosage forms, and collaborations for commercial manufacturing scale-up.
Design and conduct of clinical trials including early-stage PK/safety studies and pivotal efficacy trials for oral long-acting formulations.
Expertise Areas
- Long-acting oral drug delivery
- Gastroretentive and controlled-release formulation
- Formulation development and multi-API co-formulation
- Clinical trial management for oral dosage forms (Phase 1–3)
Key Technologies
- Gastroretentive oral dosage design
- Controlled-release oral formulation
- Multi-API co-formulation
- Pharmacokinetic characterization
News & Updates
A new drug delivery platform could enable long-acting oral pills that deliver a week or month’s worth of medicine, improving adherence and patient outcomes.
A new drug delivery platform could enable long-acting oral pills that deliver a week or month’s worth of medicine, improving adherence and patient outcomes.